EichorEICHOR
Location: Westwood Synced from ClinicalTrials.gov · August 07, 2026

Clinical studies recruiting near Westwood

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Wi
Phase 2 · University of Kansas Hospital-Westwood Cancer Center · National Cancer Institute (NCI) · NCT05564390Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small C
Phase 3 · University of Kansas Hospital-Westwood Cancer Center · NRG Oncology · NCT05624996A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Phase 1 · The University of Kansas Cancer Center - Westwood · Pfizer · NCT07206225Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated C
Phase 3 · University of Kansas Hospital-Westwood Cancer Center · Alliance for Clinical Trials in Oncology · NCT07321652Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Phase 1 · Research Site · AstraZeneca · NCT06218914Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Phase 3 · Clinical Study Site · Summit Therapeutics · NCT07228832Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyc
Phase 1 · University of Kansas Cancer Center · University of Kansas Medical Center · NCT03533816Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally A
Phase 1/Phase 2 · University of Kansas Hospital-Westwood Cancer Center · National Cancer Institute (NCI) · NCT04172532Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astr
Phase 1 · University of Kansas Hospital-Westwood Cancer Center · National Cancer Institute (NCI) · NCT06860594Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
Phase 1/Phase 2 · The University of Kansas Cancer Center · Leland Metheny · NCT03104491A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Phase 2 · University of California Los Angeles Rheumatology · Fore Biotherapeutics · NCT05503797Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM
Phase 2 · University of Kansas Hospital-Westwood Cancer Center · SWOG Cancer Research Network · NCT06769126A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone
Phase 3 · Local Institution - 0080 · Celgene · NCT05519085Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Phase 3 · University of Kansas Hospital-Westwood Cancer Center · NRG Oncology · NCT05946213Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patient
Phase 2 · University of Kansas Hospital-Westwood Cancer Center · NRG Oncology · NCT06532279Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Canc
Phase 3 · Valley Health System-Hematology/Oncology · Alliance for Clinical Trials in Oncology · NCT06632327Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastati
Phase 3 · University of Kansas Hospital-Westwood Cancer Center · Alliance for Clinical Trials in Oncology · NCT06931340ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathol
Phase 3 · University of Kansas Hospital-Westwood Cancer Center · Alliance for Clinical Trials in Oncology · NCT06876714Pan Tumor Rollover Study
Phase 2 · Local Institution - 0186 · Bristol-Myers Squibb · NCT03899155Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed
Phase 2 · The University of Kansas Cancer Center - Westwood · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT06297226Endotypic Traits and Obstructive Sleep Apnea Surgery
Phase 2 · UCLA Westwood · University of California, Los Angeles · NCT05953610Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
Phase N/A · The University of Kansas Cancer Center · University of Kansas Medical Center · NCT02302742A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Fried
Phase 3 · Biogen · NCT06953583Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SL
Phase 3 · University of Kansas Hospital-Westwood Cancer Center · National Cancer Institute (NCI) · NCT04269902A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
Phase 1/Phase 2 · The University of Kansas Cancer Center - Westwood- Site Numb · Sanofi · NCT05584670SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Phase 1 · University of Kansas Cancer Center · Verismo Therapeutics · NCT05568680Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Phase 2 · The University of Kansas Cancer Center · Regeneron Pharmaceuticals · NCT06787612A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Mye
Phase 1 · The University of Kansas Cancer Center · Incyte Corporation · NCT06034002Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NI
Phase 1 · University of Kansas Hospital-Westwood Cancer Center · National Cancer Institute (NCI) · NCT03816345A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relap
Phase 1/Phase 2 · The University of Kansas Cancer Center · BeOne Medicines · NCT06634589
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.